Migraine is a common, debilitating, long-term, neurological disorder that significantly impacts patients, the healthcare system and society as a whole.1 Approximately 10 million people regularly experience migraine attacks in the UK.2 The number of individuals living with migraine exceeds the combined total of those affected by diabetes, epilepsy and asthma.2 Migraine can affect people from all backgrounds, but notably impacts women more, with 17% of women experiencing migraines compared to 8.6% of men.2 It is the second leading cause of years lived with disability and the leading cause of disability among females aged 15 - 49 years.3
Up to 45% of people miss family, social and leisure activities due to migraine, and more than half report a significant impact on their mental health.4,5 In the UK, loss of productivity due to migraine accounts for an estimated indirect cost of £8.8 billion per year.6 The NHS direct healthcare costs for managing migraine have been estimated as up to £1 billion annually.7 2.5 million primary care appointments were linked to headache and migraine in one year.8 If referred to neurology, patients could face the longest waiting times for a first appointment compared to any other department.9
Teva is dedicated to improving the lives of those affected by migraine, going beyond just alleviating symptoms. We aim to support you in enhancing access to care and the overall quality of life for patients.
